GU Cast | Urology Podcast – Details, episodes & analysis

A big day at ESMO in Barcelona today as our friend and colleague A/Professor Arun Azad presents the results of the UpFront PSMA trial for the first time. The data were revealed in the main prostate cancer session at ESMO and simultaneously published in Lancet Oncology. UpFront PSMA is a randomised controlled trial comparing ADT and docetaxel, with ADT + done + LuPSMA in men newly diagnosed high-volume mHSPC. This is a world-first readout of LuPSMA in a prospective randomised trial for mHSPC, and clearly shows a benefit.  We dive into the details today with Arun, and another friend and colleague, Professor Michael Hofman, nuc med lead for UpFront PSMA.

This is a Themed Podcast supported by our Silver Partners, Novartis.
Even better on our YouTube channel

Full paper in Lancet Oncology here 

More than 500 salvage radical prostatectomies!!! Yep it would be fair enough to describe Dr Paul Cathcart as being "experienced" in the most challenging scenario  we face as prostate cancer surgeons. Surgery for cancer recurrence in the prostate following radiotherapy or various forms of ablative therapy is never easy, and can all too often lead to issues with healing and quality of life recovery due to the impact of prior failed treatments, so we are always keen to see how we can improve outcomes. 
Paul dropped into the GU Cast studio when back in Melbourne this week, a little over ten years on from his Fellowship training here. He is a Consultant Urologist at Guy's & St Thomas' NHS Foundation Trust in London, where his main area of expertise is indeed salvage robotic radical prostatectomy. Paul shares his perspectives and tips and tricks for performing this procedure to try and give patients the best possible outcome, and also explains why he prefers the da Vinci Surgical System over the new robot kids on the block.
This is a Themed Podcast supported by our Silver Partners, Device Technologies, distributors of the da Vinci Surgical System.

Even better on our YouTube channel

There are patient advocates and there are patient advocates, and then there is Howard Wolinsky! We chat with the inimitable Howard, medical journalist and very long-time active surveillance patient, about his varied interests in low-risk prostate cancer and prostate cancer diagnostics. He runs a great substack called The Active Surveillor with a regular newsletter which we devour every week! l His  current interests are in the abolition of transrectal prostate biopsy and the campaign to re-name grade group 1/Gleason 6 cancer as a non-cancer. We chat about all this and more, including that unforgettable appearance he made at the ASCO GU Plenary session!

Also available on our YouTube channel

Subscribe to the Active Surveillor here 

Fascinating GU Cast today focussing on the role of MRI scanning for patients on active surveillance (AS) for prostate cancer. We are joined by two of the world's leading experts on prostate MRI to discuss two recent systematic reviews on this topic.  Professor Anwar Padhani, Radiologist at Mt Vernon Cancer Centre and the Institute of Cancer Research  in London, and Professor Caroline Moore, Urologist at University College London, give some fascinating insights and tackle some controversial questions.
Patients and clinicians would love to avoid further biopsies as part of active surveillance monitoring. However, repeat biopsy remains a strong recommendation in all AS guidelines. Anwar reviews the two recent systematic reviews (links below), plus his recent European Urology editorial, and Caroline reveals what they currently offer patients at UCL (spoiler alert - they don't do routine biopsies on AS)!
Anwar also introduces the very valuable work of the International Cancer Imaging Society, and we talk about the fantastic collection of talks he posts on his very popular YouTube channel. Links all below.
Usual hosts Declan Murphy and Renu Eapen. Enjoy!

Links:
Eur Urol systematic review
Eur Urol Oncol systematic review
Anwar's Editorial in Eur Urol
Anwar's YouTube channel
International Cancer Imaging Society
Anwar's twitter
Caroline's twitter

Cracking episode today, following hot on the heels of the systematic review recently published in European Urology focussing on #manels in urology. We cross the globe to hear from first author Dr Jeremy Teoh in Hong Kong, senior author Dr Maria Ribal in Barcelona, and co-authors Dr Stacy Loeb in New York, and our own Declan Murphy in Melbourne. This paper has got a big reaction on social media and we review some of the best and the worst of twitter in our chat today. Enjoy! 

Links:
Eur Urol paper on #manels
Jeremy Teoh twitter

Big week for prostate cancer ( especially for PSMA enthusiasts like us!), with the phase III VISION trial heading the plenary session at the ASCO Annual Meeting. VISION is the long-awaited pivotal randomised trial of Lu-PSMA vs standard of care for men with progressive mCRPC following chemo +/- AR pathway inhibitors. Lots of stuff to dive into, even as we await the NEJM paper. We scrutinise the control arm and dive deep into teh issue of imaging and patient selection.
Regular hosts Professor Declan Murphy and Dr Renu Eapen are joined by some of our experienced Lu-PSMA specialists at Peter Mac, Professor Michael Hofman and Associate Professor Arun Azad.

Links;
Dr Mike Morris Twitter
UroToday report from Dr Chris Wallis

Today Declan and Renu recall one of the highlights of ASCO GU 2020 (the last real physical meeting!!),  when Dr David Penson delivered his keynote address on financial toxicity in GU Oncology. David's team also followed up with a fantastic systematic review on this completely under-discussed topic in European Urology Oncology recently (link below). David is Professor and Chair of Urology at Vanderbilt University Medical Centre in Nashville, and has had a distinguished career investigating quality of life in prostate cancer patients, particularly as PI of the Prostate Cancer Outcomes Study. No holds barred today as we discuss everything from bankruptcy-free survival to the ludicrous lack of support for de-escalation studies in GU Oncology. Plus of course, we indulge his love of golf for just a bit.

Links:
David Penson Twitter (Urogeek) - highly recommended!
Recent systematic review on financial toxicity in Eur Urol Oncol
Urotoday coverage of David's ASCO GU 2020 talk
Stacey Dusetzina twitter
Royal Portrush GC (in memory of Jimmy Penson, a proper golfer!)

GU Cast is back! Declan and Renu took a break over the Melbourne Summer and are fully recharged with a great schedule of podcasts coming up for 2021.
We kick off today with the fourth in our series of webinar collaborations with the Prostate Cancer Foundation and the ProsTIC team at Peter MacCallum Cancer Centre. Today's webinar had 589 live attendees from more than 40 countries, tuning in to hear the latest in PSMA theranostics for advanced prostate cancer. 
ON GU Cast today we cross-post the audio from today's webinar focussing on the TheraP trial, recently published in the Lancet. TheraP is the first randomised trial of 177Lutetium PSMA theranostics, and is one of the most exciting areas of research in prostate cancer today.
We are joined by both the first and senior authors, Professors Michael Hofman and Professor Ian Davis, as well as key members of the team who put this together, including funders, industry partners, and a panel of expert key opinion leaders including panellist Professor Louise Emmett.
Special thanks to Dr Howard Soule and Dr Andrea Miyahira from the PCF, as well as Professor Michael Hofman and Annette Van Der Heyden from ProsTIC for putting this together.

Links:
The PCF
ProsTIC
TheraP page at ANZUP
Full webinar on YouTube

Today we are getting together on New Year's Eve 2020 to look back on the year that was. Very forgettable for many reasons(!), but also some great moments on GU Cast that we want to share with you on our Year in Review podcast. 
Since our launch episode in March 2020, we have posted 45 episodes and have had many thousands of downloads every month. Our audience  is truly global with listeners from 75 countries in 2020,  the majority of whom (59%) are from outside Australia. 
We play back some very memorable moments from the past nine months, and chat about some of our personal highlights of GU Cast 2020. Plus we reveal our most listened to podcast this year. 
We are very grateful to the very many (>60!) national and international guests who joined the podcast this year, and to our regular studio guests who really added value to GU Cast this year. We look forward to bringing you even more great content in 2021!

Wishing you all a Happy New Year! 

Declan and Renu and all at GU Cast

We know that many of our listeners are in the depths of a tough COVID Winter in the Northern Hemisphere, so we thought we might bring you some summer cheer from Australia where the sun is shining and COVID is less of an issue! 
We have joined with our friends at PROSPECT, a prostate cancer educational initiative which has been running in Australia for eight years. to bring you a 3-part podcast summer series focussing on our favourite hot topics in prostate cancer. Today we focus on two areas with a big crossover - so-called "non-metastatic (M0)" castration-resistant prostate cancer (CRPC), and PSMA PET/CT. The past year has been a bog one for PSMA PET/CT and we are delighted to welcome two of the world's leading experts in PSMA PET/CT, Professor Michael Hofman from Peter MacCallum Cancer Centre in Melbourne, and Dr Jeremie Calais from the University of California, Los Angeles, to discuss the recent FDA approval and the data that has informed this. Plus we are joined by Associate Professor Arun Azad, Medical Oncologist at Peter MacCallum Cancer Centre and Chair of the PROSPECT Steering Committee, to discuss the overall survival data for androgen receptor pathway inhibitors in M0 CRPC, and to consider what wider availability of PSMA PET/CT means for this disease area. Your usual hosts are Professor Declan Murphy and Dr Renu Eapen from Peter Mac. 

PROSPECT and our GU Cast Summer Series are supported by an educational grant from Janssen Oncology in Australia.